Contrasting InterCure (NASDAQ:INCR) & GlucoTrack (NASDAQ:GCTK)

GlucoTrack (NASDAQ:GCTK) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability.

Profitability

This table compares GlucoTrack and InterCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-324.84%	-178.16%
InterCure	N/A	N/A	N/A

Risk and Volatility

GlucoTrack has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, InterCure has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Institutional & Insider Ownership

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 2.2% of GlucoTrack shares are held by company insiders. Comparatively, 0.2% of InterCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares GlucoTrack and InterCure”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39 million	($55.51)	-0.01
InterCure	$243.12 million	0.17	-$18.32 million	$0.03	29.96

InterCure has higher revenue and earnings than GlucoTrack. GlucoTrack is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for GlucoTrack and InterCure, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1	0	0	0	1.00
InterCure	1	0	0	0	1.00

Summary

InterCure beats GlucoTrack on 7 of the 9 factors compared between the two stocks.

About GlucoTrack

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.